Hi @lufun,
There have been controversies over this based on the difference in people treated with either entecavir or tenofovir. Because entecavir was released first, we have more data on it and people who have been on it for longer. People on tenofovir are more likely to be more recently diagnosed. This could lead to a difference in observed HCC rates. My understanding is that once these differences are controlled for, then both entecavir and tenofovir are pretty much equal in preventing liver cancer (about 80% reduction in HCC risk).
Happy for other @ScienceExperts or @HealthExperts to correct me or add any additional points.
TT